Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study

7003 Background: Lumiliximab is an anti-CD23 monoclonal antibody that is being investigated for the treatment of relapsed B-cell CLL (BCLL). CD23 is a glycoprotein expressed on the majority of CLL ...